Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 17/20 | 0.65 |
| ▸ | PPARA | Q07869 | 16/20 | 0.65 |
| ▸ | PPARD | Q03181 | 8/20 | 0.65 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
| ▸ | FABP2 | P12104 | 1/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL376724 | 0.95 | PPARA (0.67) | PPARGPPARAPPARDNR1H4FABP2 | |
| SCHEMBL376825 | 0.89 | PPARA (0.68) | PPARGPPARAPPARDNR1H4 | |
| SCHEMBL377030 | 0.88 | PPARA (0.59) | PPARGPPARAPPARDFABP2SLC22A12 | |
| SCHEMBL376733 | 0.87 | PPARA (0.58) | PPARGPPARAPPARDFABP2SLC22A12 | |
| SCHEMBL376936 | 0.86 | PPARA (0.64) | PPARGPPARAPPARDNR1H4FABP2 | |
| SCHEMBL7102199 | 0.86 | PPARD (0.49) | PPARGPPARAPPARDNR1H4 | |
| SCHEMBL376767 | 0.85 | PPARA (0.58) | PPARGPPARAPPARD | |
| SCHEMBL377239 | 0.85 | PPARA (0.55) | PPARGPPARAPPARD | |
| SCHEMBL1765972 | 0.84 | PPARA (0.69) | PPARGPPARAPPARDFABP2SLC22A12 | |
| SCHEMBL377166 | 0.83 | PPARA (0.66) | PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1310494-B1 | PPAR (delta) ACTIVATORS | NIPPON CHEMIPHAR CO (JP) | 2012-01-25 | — | — | EP | disclosed |
| US-6787552-B2 | HYPERGLYCEMIA, HYPERLIPIDEMIA, OBESITY, SYNDROME X; OXAZOLE OR THIAZOLE OR IMIDAZOLE DERIVATIVES | NIPPON CHEMIPHAR CO., LTD. (JP) | 2004-09-07 | — | — | US | disclosed |
| US-20040097739-A1 | Ppar delta activators | NIPPON CHEMIPHAR CO., LTD. (JP) | 2004-05-20 | — | — | US | disclosed |
| EP-1310494-A1 | PPAR (delta) ACTIVATORS | NIPPON CHEMIPHAR CO., LTD. (JP) | 2003-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097739-A1 | Ppar delta activators | PPARD, PPARG, PPARA | PPARG 2/4885PPARA 3/4885PPARD 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.